Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: Results of an open-label study

Journal of Clinical Psychiatry

Volumn 59, Issue 2, 1998, Pages 56-59

  Buitelaar, Jan K ^a,d   Van Der Gaag, Rutger Jan ^a,b   Van Der Hoeven, Joost ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Utrecht and the Veldwijk Res Inst   (Netherlands)

^c Zonnehuizen Veldheim Stenia   (Netherlands)

^d Department of Child Psychiatry ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CLONIDINE; HALOPERIDOL; METHYLPHENIDATE; PIMOZIDE;

ADOLESCENT; AGITATION; ANXIETY NEUROSIS; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IRRITABILITY; MALE; MOOD; NAUSEA; PRIORITY JOURNAL; TREMOR; VERTIGO;

EID: 0031938577     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n0203     Document Type: Article

References (24)

1. Buitelaar JK. Psychopharmacological approaches to childhood psychotic disorders. In: Den Boer JA, Westenberg HGM, Van Praag HM, eds. Advances in the Neurobiology of Schizophrenia. New York, NY: John Wiley & Sons; 1995:429-457
2. Cohen DJ, Paul R, Volkmar FR. Issues in the classification of pervasive and other developmental disorders: toward DSM-IV. J Am Acad Child Psychiatry 1986;25:213-220
3. Towbin KE, Dykens EM, Pearson GS, et al. Conceptualizing "borderline syndrome of childhood" and "childhood schizophrenia" as a developmental disorder. J Am Acad Child Adolesc Psychiatry 1993;32:775-782
4. van der Gaag RJ. Multiplex Developmental Disorder: An Exploration of Borderlines on the Autistic Spectrum. Utrecht, the Netherlands: University of Utrecht; 1993. Thesis
5. van der Gaag RJ, Buitelaar JK, Van den Ban E, et al. A controlled multivariate chart review of multiple complex developmental disorder. J Am Acad Child Adolesc Psychiatry 1995;34:1096-1106
6. Campbell M, Anderson LT, Meier M, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 1978;17:640-655
7. Anderson LT, Campbell M, Graga DM, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984;141:1195-1202
8. Anderson LT, Campbell M, Adams P, et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989;19:227-239
9. Fisher W, Kerbeshian J, Burd L. A treatable language disorder: pharmacological treatment of pervasive developmental disorder. J Dev Behav Pediatr 1986;7:73-76
10. Joshi PT, Capozzoli JA, Coyle JT. Low-dose neuroleptic therapy for children with childhood-onset pervasive developmental disorder. Am J Psychiatry 1988;145:335-338
11. Campbell M, Adams P, Perry R, et al. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull 1988;24: 251-255
12. Gedye A. Buspirone alone or with serotonergic diet reduced aggression in developmentally disabled adults. Biol Psychiatry 1991;30:88-91
13. Ratey JJ, Sovner R, Mikkelsen E, et al. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry 1989;50:382-384
14. Ratey J, Sovner R, Parks A, et al. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. J Clin Psychiatry 1991;52:159-162
15. Realmuto GM, August GJ, Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 1989;9:122-125
16. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
17. Van Praag HM, Asnis GM, Kahn RS, et al. Monoamines and abnormal behaviour: a multi-aminergic perspective. Br J Psychiatry 1990;157: 723-734
18. Apter A, Van Praag HM, Plutchnik R. Interrelationships among anxiety, aggression, impulsivity and mood: a serotonergically linked cluster? Psychiatry Res 1990;32:191-199
19. Kruesi MJP, Rapoport JL, Hamburger S, et al. CSF monoamine metabolites, aggression and impulsivity in disruptive behavior disorders of children and adolescents. Arch Gen Psychiatry 1990;47:419-426
20. Van Praag HM. Serotonergic dysfunction and aggression control [editorial]. Psychol Med 1991;21:15-19
21. McBride PA, Anderson GM, Hertzig ME, et al. Serotonergic responsivity in male young adults with autistic disorder. Arch Gen Psychiatry 1989;46: 213-221
22. LeWitt PA, Walters A, Hening W, et al. Persistent movement disorders induced by buspirone. Mov Disord 1993;8:331-334
23. Wood PL, Nair NP, Lal S, et al. Buspirone: a potential atypical neuroleptic. Life Sci 1983;33:269-273
24. Cimino M, Ponzio F, Achilli G, et al. Dopaminergic effects of buspirone, a novel anxiolytic agent. Biochem Pharmacol 1983;32:1069-1074